FDA Approves Weight Loss Medication Zepbound As First Treatment For Sleep Apnea

The FDA approved Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a GLP-1 medication approved to treat obesity or overweight. About half of the adults taking Zepbound no longer had symptoms associated with OSA after one year.

OSA is a sleep-related breathing disorder characterized by complete or partial collapses of the upper airway during sleep. Averaging up to 20% in weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept.

The approval was based on results . . .